Peptide record

TPDB84089

Pexiganan MSI-78 Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard modified_plain modified
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB84089
Pexiganan MSI-78
Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Immunity and inflammation peptides Toxicity and safety peptides
Peptipedia AntiBP3 dbAMP DRAMP ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb i2APP HemoPI Hemolytic2 PD_Hemolysis DBAASP
standard modified_plain
Yes
A 22-aa standard-residue and modified multi-activity (Anti-inflammatory, Antibacterial, Anticancer, and other sources) peptide sequence curated from Peptipedia, AntiBP3, dbAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIGKFLKKAKKFGKAFVKILKK-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
22 reviewed residue count
Amidation AMD Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Anticancer Activity
Helical peptide with a predominance of one or more amino acids tryptophane-rich FLAK peptides Analog of Magainin Analog of magainin 2 Activity
Evidence Records 12 records
Evidence 1 Activity

Activity

75% Cytotoxicity at 0.5 µg/ml
Anticancer

Target

Lymphoma Cancer
U-937
Blood

Assay & Model

MTT/MTS assay
6-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
1994

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =31 µg/ml
Anticancer
31 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =34 µg/ml
Anticancer
34 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =140 µg/ml
Anticancer
140 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =150 µg/ml
Anticancer
150 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =66 µg/ml
Anticancer
66 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

Not Available
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 8 Activity

Activity

IC50
IC50 =20-30 µg/ml
Anticancer
20-30 µg/mL

Target

Lymphoma Cancer
U-941
Blood

Assay & Model

MTT/MTS assay
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2011
Evidence 9 Activity

Activity

LC50
LC50= 8 at 100 µM
Anticancer
8

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2014
Evidence 10 Activity

Activity

LC50
LC50= 6 at 100 µM
Anticancer
6

Target

Prostate cancer
LNCaP
Prostate

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2014
Evidence 11 Activity

Activity

LC50
LC50= 13 at 100 µM
Anticancer
13

Target

Ovarian Cancer
OVRCAR-3
Ovary

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2014
Evidence 12 Activity

Target

Cutibacterium acnes

Source & Reference

DBAASP